CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Tonix.

新泽西州查塔姆，2024年6月11日（环球通讯社）--Tonix Pharmaceuticals Holding Corp.（纳斯达克代码：TNXP）（“Tonix”或“公司”）是一家完全整合的生物制药公司，今天宣布，它打算发行和出售其普通股（或替代其的预先出资权证）的股票。本次发行中出售的所有证券均由Tonix发行。

The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness.Dawson James Securities, Inc.

本次发行受市场条件限制，无法保证是否或何时完成本次发行，也无法保证本次发行的实际规模或条款。本公司打算将本次发行的净收益用于营运资金和一般企业用途，包括为纤维肌痛患者准备与其Tonmya™候选产品相关的新药申请，以及偿还其现有债务的任何部分。道森詹姆斯证券公司。

is the sole placement agent for the offering.This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-266982) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and accompanying prospectus.

是本次发行的唯一配售代理。本次发行是根据先前向美国证券交易委员会（“SEC”）提交的表格S-3（文件号333-266982）上的有效货架登记声明进行的。本次发行将仅通过补充招股说明书和随附招股说明书的方式进行。

The preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement may be obtained, when available, from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432 or by telephone at (561) 391-5555, or by email at investmentbanking@dawsonjames.com.

初步补充招股说明书和描述拟议发售条款的随附招股说明书将提交给美国证券交易委员会，并可在美国证券交易委员会的网站上查阅http://www.sec.gov.初步补充招股说明书的电子副本可从道森詹姆斯证券有限公司（地址：101 North Federal Highway，Suite 600，Boca Raton，FL 33432）或电话（561）391-5555或电子邮件investmentbanking@dawsonjames.com.

Before investing in this offering, interested parties should read in their entirety the pros.

在投资此产品之前，感兴趣的各方应该全面阅读专业人士的意见。